Drug Trial Radar · NCT05776914
Fecal Microbiota Transplantation for IBS
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
43
Planned (sponsor's estimate)
Start
Apr 15, 2024
Primary completion
Jun 26, 2027
Study completion Jun 26, 2027
Sponsor
- Lead sponsor
- Madhusudan (Madhu) Grover, MBBSAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn the efficacy and safety of fecal microbiota transplantation (FMT) using stool from a donor with low proteolytic activity and containing the bacteria Alistipes putredinis in patients with irritable bowel syndrome (IBS) and high proteolytic activity. Proteolytic activity is the breakdown of proteins into smaller polypeptides or amino acids.
Conditions
- Irritable Bowel Syndrome
- Diarrhea
Interventions
Donor Fecal Microbiota TransplantationBiological
Single fecal microbiota transplantation using 50 gm of freeze-thawed donor stool
Autologous Fecal Microbiota TransplantationBiological
Single fecal microbiota transplantation using 50 gm of stool collected from the same individual
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of respondersTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Minnesota
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.